115 related articles for article (PubMed ID: 30446316)
1. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients.
Munck Af Rosenschold P; Law I; Engelholm S; Engelholm SA; Muhic A; Lundemann MJ; Roed H; Grunnet K; Skovgaard Poulsen H
Radiother Oncol; 2019 Jan; 130():149-155. PubMed ID: 30446316
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.
Poulsen SH; Urup T; Grunnet K; Christensen IJ; Larsen VA; Jensen ML; Af Rosenschöld PM; Poulsen HS; Law I
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):373-381. PubMed ID: 27554774
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
[TBL] [Abstract][Full Text] [Related]
4. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
5. Hippocampal sparing radiotherapy for glioblastoma patients: a planning study using volumetric modulated arc therapy.
Hofmaier J; Kantz S; Söhn M; Dohm OS; Bächle S; Alber M; Parodi K; Belka C; Niyazi M
Radiat Oncol; 2016 Sep; 11(1):118. PubMed ID: 27609371
[TBL] [Abstract][Full Text] [Related]
6. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.
Piroth MD; Galldiks N; Pinkawa M; Holy R; Stoffels G; Ermert J; Mottaghy FM; Shah NJ; Langen KJ; Eble MJ
Radiat Oncol; 2016 Jun; 11():87. PubMed ID: 27342976
[TBL] [Abstract][Full Text] [Related]
7. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
[TBL] [Abstract][Full Text] [Related]
8. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study.
Piroth MD; Pinkawa M; Holy R; Klotz J; Schaar S; Stoffels G; Galldiks N; Coenen HH; Kaiser HJ; Langen KJ; Eble MJ
Strahlenther Onkol; 2012 Apr; 188(4):334-9. PubMed ID: 22349712
[TBL] [Abstract][Full Text] [Related]
9. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
Suchorska B; Jansen NL; Linn J; Kretzschmar H; Janssen H; Eigenbrod S; Simon M; Pöpperl G; Kreth FW; la Fougere C; Weller M; Tonn JC;
Neurology; 2015 Feb; 84(7):710-9. PubMed ID: 25609769
[TBL] [Abstract][Full Text] [Related]
10. 5-Aminolevulinic Acid Fluorescence-Guided Resection of 18F-FET-PET Positive Tumor Beyond Gadolinium Enhancing Tumor Improves Survival in Glioblastoma.
Müther M; Koch R; Weckesser M; Sporns P; Schwindt W; Stummer W
Neurosurgery; 2019 Dec; 85(6):E1020-E1029. PubMed ID: 31215632
[TBL] [Abstract][Full Text] [Related]
11. Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy.
Navarria P; Pessina F; Cozzi L; Ascolese AM; Lobefalo F; Stravato A; D'Agostino G; Franzese C; Caroli M; Bello L; Scorsetti M
BMC Cancer; 2016 Jun; 16():362. PubMed ID: 27287048
[TBL] [Abstract][Full Text] [Related]
12. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Irradiation Boost Based on 18F-FET-PET in Patients with Newly Diagnosed Glioblastoma.
Harat M; Blok M; Miechowicz I; Wiatrowska I; Makarewicz K; Małkowski B
Clin Cancer Res; 2022 Jul; 28(14):3011-3020. PubMed ID: 35552391
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[
Harat M; Małkowski B; Roszkowski K
Radiat Oncol; 2019 Mar; 14(1):37. PubMed ID: 30832691
[TBL] [Abstract][Full Text] [Related]
15. Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.
Popp I; Bott S; Mix M; Oehlke O; Schimek-Jasch T; Nieder C; Nestle U; Bock M; Yuh WTC; Meyer PT; Weber WA; Urbach H; Mader I; Grosu AL
Radiother Oncol; 2019 Jan; 130():121-131. PubMed ID: 30219612
[TBL] [Abstract][Full Text] [Related]
16. Patterns of failure for patients with glioblastoma following O-(2-[
Lundemann M; Costa JC; Law I; Engelholm SA; Muhic A; Poulsen HS; Munck Af Rosenschold P
Radiother Oncol; 2017 Mar; 122(3):380-386. PubMed ID: 28110959
[TBL] [Abstract][Full Text] [Related]
17. Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme.
Chen YD; Feng J; Fang T; Yang M; Qiu XG; Jiang T
Chin Med J (Engl); 2013 Jun; 126(12):2320-4. PubMed ID: 23786946
[TBL] [Abstract][Full Text] [Related]
18. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
[TBL] [Abstract][Full Text] [Related]
19. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
[TBL] [Abstract][Full Text] [Related]
20. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
